{"id":44800,"date":"2022-06-07T17:01:19","date_gmt":"2022-06-07T15:01:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/"},"modified":"2022-06-07T17:01:19","modified_gmt":"2022-06-07T15:01:19","slug":"agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/","title":{"rendered":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines"},"content":{"rendered":"
\n

\nCloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data\n<\/p>\n

<\/a><\/p>\n

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc.<\/a> (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS) Graviton2 processors and featuring NVIDIA T4G Tensor Core GPUs, in combination with NVIDIA<\/a> Clara Parabricks<\/a>\u2019 advanced genomics analysis capabilities, to significantly improve processing speeds for variant calling workflows on Agilent\u2019s cloud-native Alissa Reporter<\/a> software.\n<\/p>\n

\nThis collaboration enables Agilent to offer streamlined workflow solutions for its SureSelect family of next-generation sequencing (NGS) assays comprising a wide range of custom and catalog panels, including SureSelect Human Exome reagents. The integration of NVIDIA Clara Parabricks platform with the Alissa secondary analysis pipelines enables clinical labs and researchers to benefit from fast panel-specific data analysis solutions in a secure and user-friendly cloud software environment.\n<\/p>\n

\n\u201cAgilent\u2019s SureSelect panels are widely utilized to enrich samples for specific genes of interest, enabling cost-effective targeted sequencing. We\u2019re now able to leverage our bioinformatics expertise, in combination with NVIDIA\u2019s compute expertise, to offer our customers optimized analysis solutions through a combination of Agilent\u2019s optimized variant calling algorithms and NVIDIA\u2019s accelerated compute capabilities,\u201d said Kevin Meldrum, Vice President and General Manager of Agilent\u2019s Integrated Genomics Division.\n<\/p>\n

\n\u201cWe\u2019re also excited to extend our collaboration with AWS to further leverage its data security capabilities and global reach, so we can offer cloud-based analysis capabilities to customers on a global basis,\u201d Meldrum added.\n<\/p>\n

\n\u201cAs the scale and scope of genomics experiments accelerates, reducing analysis turnaround times is more important than ever,\u201d said George Vacek, Global Director of Genomics Alliances at NVIDIA. \u201cThe integration of NVIDIA Clara Parabricks with Agilent\u2019s Alissa Reporter software package will enable clinical labs and researchers to improve the efficiency and costs associated with NGS data analysis, helping to advance genomics discovery and medicine.\u201d\n<\/p>\n

\n\u201cWorking with Agilent and NVIDIA, we are giving genomics customers worldwide the ability to take advantage of and innovation with AWS\u2019s secure and transformative cloud computing capabilities that offer the best cost and performance globally. Running genomics workloads in the cloud, allows customers to focus on the important work they are doing to speed insights and achieve scientific breakthroughs that uncover novel and lifesaving products,\u201d said Ankit Malhotra, Genomics Lead, Healthcare, Worldwide Public Sector at Amazon Web Services. \u201cWe look forward to our continuing collaboration with both companies to help advance genomic discoveries supported by the cloud. Agilent is committed to working with AWS and NVIDIA to continually advance genomic data analysis capabilities, including region-specific adaptations to meet local security and compliance criteria.\u201d\n<\/p>\n

\nAbout Agilent Technologies<\/b>\n<\/p>\n

\nAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent\u2019s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com<\/a>. To receive the latest Agilent news, please subscribe to the Agilent Newsroom<\/a>. Follow Agilent on LinkedIn<\/a>, Twitter<\/a>, and Facebook<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Naomi Goumillout
\n
Agilent Technologies
\n
+1.781.266.2819
\n
naomi.goumillout@agilent.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS) Graviton2 processors … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44800","6":"format-standard","7":"category-industry"},"yoast_head":"\nAgilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS) Graviton2 processors ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T15:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines\",\"datePublished\":\"2022-06-07T15:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/\"},\"wordCount\":573,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006006\\\/en\\\/1478991\\\/21\\\/AgilentLogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/\",\"name\":\"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006006\\\/en\\\/1478991\\\/21\\\/AgilentLogo.jpg\",\"datePublished\":\"2022-06-07T15:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006006\\\/en\\\/1478991\\\/21\\\/AgilentLogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006006\\\/en\\\/1478991\\\/21\\\/AgilentLogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/","og_locale":"en_US","og_type":"article","og_title":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend","og_description":"Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS) Graviton2 processors ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-07T15:01:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines","datePublished":"2022-06-07T15:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/"},"wordCount":573,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/","url":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/","name":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg","datePublished":"2022-06-07T15:01:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220607006006\/en\/1478991\/21\/AgilentLogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/agilent-leverages-nvidia-and-aws-technology-to-improve-analysis-speeds-of-genomics-bioinformatics-pipelines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44800"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44800\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}